Abstract
Prostate cancer is the second most common cause of male cancer deaths in the UK. It is one of the few hormone-sensitive cancers and androgen ablation produces subjective and objective tumour regression in 70-80% of patients for a variable period. Orchidectomy remains the gold standard for treatment although there is an increasing number of equally effective medical alternatives.
MeSH terms
-
Androgen Antagonists / administration & dosage
-
Androgen Antagonists / pharmacology
-
Androgen Antagonists / therapeutic use
-
Combined Modality Therapy
-
Gonadotropin-Releasing Hormone / analogs & derivatives
-
Humans
-
Male
-
Orchiectomy
-
Palliative Care
-
Prostatic Neoplasms / mortality
-
Prostatic Neoplasms / pathology
-
Prostatic Neoplasms / therapy*
-
Sexual Behavior / drug effects
-
Survival Rate
Substances
-
Androgen Antagonists
-
Gonadotropin-Releasing Hormone